SYK, spleen associated tyrosine kinase, 6850

N. diseases: 229; N. variants: 7
Disease: B-Cell Lymphomas ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas 		0.040 Biomarker group BEFREE Areas covered: This review covers both approved inhibitors and investigational inhibitors of spleen tyrosine kinase (SYK), Bruton's tyrosine kinase (BTK), and phosphoinositide-3-kinase (PI3K) in the treatment of B-cell lymphomas. 29781323 2018
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas 		0.040 Biomarker group BEFREE Kinases spleen tyrosine kinase (Syk), Src, and Janus kinase 2 (JAK2) have been thought as potential targets for the treatment of BCL. 29340070 2017
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas 		0.040 GeneticVariation group BEFREE Together with B cell lymphoma (Bcl)10 and the paracaspase, mucosa-associated lymphoid tissue lymphoma translocation protein (Malt)1, Card9 links spleen-tyrosine kinase (Syk)-coupled C-type lectin receptors to inflammatory responses. 23523010 2013
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas 		0.040 Biomarker group LHGDN SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. 18006696 2008